Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with B-cell non-Hodgkin's lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing POZIOTINIB for treating breast and lung cancer; ROLONTIS for chemotherapy-induced neutropenia; and QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. The company sells its drugs through group purchasing organizations, wholesalers, and directly in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SPPI
CUSIP84763A10
Phone702-835-6300
Debt
Debt-to-Equity RatioN/A
Current Ratio2.97
Quick Ratio2.91
Price-To-Earnings
Trailing P/E Ratio-22.46
Forward P/E Ratio-26.41
P/E GrowthN/A
Sales & Book Value
Annual Sales$128.37 million
Price / Sales19.48
Cash FlowN/A
Price / CashN/A
Book Value$3.49 per share
Price / Book6.89
Profitability
EPS (Most Recent Fiscal Year)($1.07)
Net Income$-91,240,000.00
Net Margins-64.39%
Return on Equity-29.47%
Return on Assets-19.00%
Miscellaneous
Employees215
Outstanding Shares104,060,000
Market Cap$2,397.43
Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions
What is Spectrum Pharmaceuticals' stock symbol?
Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."
How were Spectrum Pharmaceuticals' earnings last quarter?
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) posted its earnings results on Thursday, May, 3rd. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.35) by $0.19. The biotechnology company had revenue of $30.50 million for the quarter, compared to analyst estimates of $25.68 million. Spectrum Pharmaceuticals had a negative return on equity of 29.47% and a negative net margin of 64.39%. Spectrum Pharmaceuticals's revenue was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.14) EPS. View Spectrum Pharmaceuticals' Earnings History.
What price target have analysts set for SPPI?
4 brokerages have issued 1 year price targets for Spectrum Pharmaceuticals' stock. Their forecasts range from $25.00 to $33.00. On average, they anticipate Spectrum Pharmaceuticals' stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 20.7% from the stock's current price. View Analyst Ratings for Spectrum Pharmaceuticals.
What is the consensus analysts' recommendation for Spectrum Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Spectrum Pharmaceuticals' key competitors?
Some companies that are related to Spectrum Pharmaceuticals include Sarepta Therapeutics (SRPT), Beigene (BGNE), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS), United Therapeutics (UTHR), FibroGen (FGEN), Loxo Oncology (LOXO), GALAPAGOS NV/S (GLPG), Agios Pharmaceuticals (AGIO), Dr.Reddy's Laboratories (RDY) and Ligand Pharmaceuticals (LGND).
Who are Spectrum Pharmaceuticals' key executives?
Spectrum Pharmaceuticals' management team includes the folowing people:
- Mr. Joseph W. Turgeon, Pres, CEO & Director (Age 60)
- Mr. Kurt A. Gustafson, Exec. VP & CFO (Age 50)
- Mr. Thomas J. Riga, Exec. VP, COO & Chief Commercial Officer (Age 42)
- Mr. Shivpreet Kapoor, VP of Strategic Planning & Investor Relations
- Mr. Keith M. McGahan J.D., L.L.M., Sr. VP & Chief Legal Officer
Has Spectrum Pharmaceuticals been receiving favorable news coverage?
News coverage about SPPI stock has been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Spectrum Pharmaceuticals earned a news impact score of 0.20 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 46.36 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Spectrum Pharmaceuticals' major shareholders?
Spectrum Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.15%), Bank of Montreal Can (0.14%), Fox Run Management L.L.C. (0.02%) and Amalgamated Bank (0.02%). Company insiders that own Spectrum Pharmaceuticals stock include Joseph W Turgeon, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Institutional Ownership Trends for Spectrum Pharmaceuticals.
Which major investors are selling Spectrum Pharmaceuticals stock?
SPPI stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC and Bank of Montreal Can. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Joseph W Turgeon, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Insider Buying and Selling for Spectrum Pharmaceuticals.
Which major investors are buying Spectrum Pharmaceuticals stock?
How do I buy shares of Spectrum Pharmaceuticals?
Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spectrum Pharmaceuticals' stock price today?
One share of SPPI stock can currently be purchased for approximately $24.03.
How big of a company is Spectrum Pharmaceuticals?
Spectrum Pharmaceuticals has a market capitalization of $2.40 billion and generates $128.37 million in revenue each year. The biotechnology company earns $-91,240,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Spectrum Pharmaceuticals employs 215 workers across the globe.
How can I contact Spectrum Pharmaceuticals?
Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]
MarketBeat Community Rating for Spectrum Pharmaceuticals (NASDAQ SPPI)
MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe SPPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPPI will underperform the S&P 500 over the long term. You may vote once every thirty days.
